Stock code：600380 Stock abbreviation：健康元
Joincare Pharmaceutical Group Industry Co., Ltd
2022 First Quarterly Report
Board of Directors (the “Board”) and all Directors of the Company hereby warrant that there are no
false representations, misleading statements or material omissions contained in this report, and
severally and jointly accept responsibility for the truthfulness, accuracy and completeness of the
contents of the Report.
IMPORTANT NOTICE
(I) The Board, the Supervisory Committee and the Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of
quarterly reports, and that there are no false representations, misleading statements or material
omissions contained in the Report, and severally and jointly accept responsibility.
(II) Theperson-in-chargeoftheCompany,theperson-in-chargeoftheCompany'saccountingwork
and the person-in-charge of the accounting department(the head of theaccounting department)
hereby warrant the truthfulness, accuracy and completeness of the financial statements
contained in quarterly reports.
(III) Whether the first quarterly financial statements are audited
□Applicable √N/A
(IV) The Report is prepared in both Chinese and English. In case of any ambiguity in the
understanding of the Chinese and English texts, the Chinese version shall prevail.
I Principal Financial Data
(I) Principal accounting data and financial indicators
Unit: Yuan Currency: RMB
Item The Reporting Period: Year-on-Year Change (%)
(January-March 2022)
Revenues 4,657,343,538.89 12.36
Net profit attributable to Shareholders of 460,537,813.53 25.52
the listed company
Net profit attributable to Shareholders of
the listed company after deducting the 457,193,702.95 36.47
extraordinary gain or loss
Net cash flow from operating activities 871,904,476.98 76.27
Basic earnings per share (RMB/share) 0.2411 28.49
Diluted earnings per share (RMB/share) 0.2410 28.72
Weighted average return on net assets (%) 3.84 Increased by 0.58 percentage points
Change from the end
End of the End of the Previous Year of the previous year to
Reporting Period the end of the
Reporting Period (%)
Total assets 32,275,092,753.15 31,103,900,389.29 3.77
Owners’ equity attributable
to Shareholders of the listed 12,073,975,596.59 11,820,293,656.69 2.15
company
Note: During the Reporting Period, the Company recorded revenues of RMB 4,657 million,
representing an increase of 12.36% year-on-year; the main driver of the growth is steady increasing
sales volume of main product categories in key specialist arenas. During the first quarter of 2022,
Revenues from chemical drug preparation products amounted to RMB 2,737 million, representing
an increase of 24.54% year-on-year, of which, Revenues from Inhalation products amounted to 363
million, representing an increase of 324.90% year-on-year; Revenues from anti-infective drugs
amounted to RMB 350 million, representing an increase of 26.91% year-on-year; Revenues from
gastroenterologyproducts amounted to RMB 1,070million, representing anincreaseof 5.90%year-
on-year; Revenues from gonadotropic hormones products amounted to RMB 737 million,
representing an increase of 22.84% year-on-year; Revenues from APIs and intermediates amounted
to RMB 1,406 million, representing an increase of 14.90% year-on-year. The Revenues from
traditional Chinese medicine preparations amounted to RMB 283 million, representing a decrease
of 33.53% year-on-year. The Revenues fromdiagnostic reagents and equipmentproducts amounted
to RMB162 million, representing a decrease of 30.77% year-on-year.
(II) Items and amounts of extraordinary gains and losses
Unit: Yuan Currency: RMB
Item Amounts for the Explanation
Reporting Period
Gains and losses on disposal of non-current -374,417.51 Proceeds from disposal of fixed
assets assets
Government grants included in profit and
loss for the Period (except for government
g
查看PDF原文
